PE115499A1 - Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas de la prostaglandina f (fp) - Google Patents

Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas de la prostaglandina f (fp)

Info

Publication number
PE115499A1
PE115499A1 PE1998000843A PE00084398A PE115499A1 PE 115499 A1 PE115499 A1 PE 115499A1 PE 1998000843 A PE1998000843 A PE 1998000843A PE 00084398 A PE00084398 A PE 00084398A PE 115499 A1 PE115499 A1 PE 115499A1
Authority
PE
Peru
Prior art keywords
alkyl
heteroalkyl
useful
aromatic
prostaglandin
Prior art date
Application number
PE1998000843A
Other languages
English (en)
Inventor
John August Wos
Jr Jack S Amburgey
Mitchell Anthony Delong
Yili Wang
Biswanath De
Haiyan George Dai
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE115499A1 publication Critical patent/PE115499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5, TETRAZOL; R5 ES ALQUILO, HETEROALQUILO, CARBOCICLO, HETEROCICLO, ANILLO AROMATICO O HETEROAROMATICO; R2 ES H O ALQUILO; X ES NR6R7, OR8, SR9, S(O)2R9; R6, R7 Y R8 SON H, ACILO, ALQUILO, HETEROALQUILO, ENTRE OTROS; R9 ES ALQUILO, HETEROALQUILO, CARBOCICLO, ANILLO AROMATICO O HETEROAROMATICO; R3 Y R4 SON H, CH3, C2H5; Y ES NR10, S, S(O) o S(O)2; R10 ES H, ACILO, ALQUILO, HETEROALQUILO, ENTRE OTROS; Z ES UN CARBOCICLO, HETEROCICLO, AROMATICO O HETEROAROMATICO. UN COMPUESTO PREFERIDO ES 13,14-DIHIDRO-16-(3-METILFENILTIO)TETRANORPROSTAGLANDINA F1O METIL ESTER, ENTRE OTROS. EL COMPUESTO I PUEDE SER UTIL PARA TRATAR UN TRASTORNO OSEO COMO OSTEOPOROSIS POSTMENOPAUSICA, OSTEOPOROSIS INDUCIDA POR CORTICOESTEROIDES, OSTEOPENIA, FRACTURA DE HUESO, GLAUCOMA
PE1998000843A 1997-09-09 1998-09-08 Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas de la prostaglandina f (fp) PE115499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5821797P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
PE115499A1 true PE115499A1 (es) 2000-02-03

Family

ID=22015427

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000843A PE115499A1 (es) 1997-09-09 1998-09-08 Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas de la prostaglandina f (fp)

Country Status (24)

Country Link
US (1) US5977173A (es)
EP (1) EP1012136B1 (es)
JP (1) JP2001515882A (es)
KR (1) KR20010023839A (es)
CN (1) CN1269786A (es)
AR (1) AR013477A1 (es)
AT (1) ATE270660T1 (es)
AU (1) AU731153B2 (es)
BR (1) BR9811774A (es)
CA (1) CA2303764C (es)
CO (1) CO4970731A1 (es)
DE (1) DE69824966T2 (es)
ES (1) ES2223141T3 (es)
HU (1) HUP0100638A3 (es)
ID (1) ID23971A (es)
IL (1) IL134839A0 (es)
NO (1) NO20001141L (es)
NZ (1) NZ503735A (es)
PE (1) PE115499A1 (es)
PL (1) PL339212A1 (es)
SK (1) SK3372000A3 (es)
TR (1) TR200000671T2 (es)
WO (1) WO1999012895A1 (es)
ZA (1) ZA988230B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AU776375B2 (en) 1999-08-04 2004-09-09 Duke University Novel 2-decarboxy-2-phosphinico prostaglandin F analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20060135609A1 (en) 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
RU2010121880A (ru) * 2007-10-31 2011-12-10 Памела ЛИПКИН (US) Композиции аналогов простагландина и способы лечения состояний, затрагивающих эпителий
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2349242B1 (en) 2008-10-29 2018-12-05 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010077101A2 (ko) 2008-12-30 2010-07-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
EP3811943B1 (en) 2013-03-15 2023-02-22 Aerie Pharmaceuticals, Inc. Compound for use in the treatment of ocular disorders
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
BR112019003945A2 (pt) 2016-08-31 2019-05-21 Aerie Pharmaceuticals, Inc. composições oftálmicas
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
IL50310A (en) * 1972-11-08 1977-08-31 Pfizer Dimethyl ketophosphonates
JPS5720305B2 (es) * 1973-02-28 1982-04-27
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2460990A1 (de) * 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB1506817A (en) * 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
US4051238A (en) * 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
DE2737808A1 (de) * 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4206151A (en) * 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
JP2721414B2 (ja) * 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (es) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5332730A (en) * 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag, Zug Endothelin-antagonisten
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6353014B1 (en) * 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy

Also Published As

Publication number Publication date
TR200000671T2 (tr) 2000-07-21
HUP0100638A3 (en) 2002-12-28
EP1012136B1 (en) 2004-07-07
NO20001141D0 (no) 2000-03-06
JP2001515882A (ja) 2001-09-25
PL339212A1 (en) 2000-12-04
IL134839A0 (en) 2001-05-20
CA2303764A1 (en) 1999-03-18
ES2223141T3 (es) 2005-02-16
EP1012136A1 (en) 2000-06-28
ID23971A (id) 2000-06-14
NZ503735A (en) 2001-05-25
SK3372000A3 (en) 2000-10-09
CN1269786A (zh) 2000-10-11
NO20001141L (no) 2000-05-04
DE69824966D1 (de) 2004-08-12
HUP0100638A2 (hu) 2001-07-30
US5977173A (en) 1999-11-02
AU731153B2 (en) 2001-03-22
ZA988230B (en) 1999-03-09
DE69824966T2 (de) 2005-04-07
WO1999012895A1 (en) 1999-03-18
AU9219398A (en) 1999-03-29
KR20010023839A (ko) 2001-03-26
BR9811774A (pt) 2000-08-29
ATE270660T1 (de) 2004-07-15
CA2303764C (en) 2005-02-15
CO4970731A1 (es) 2000-11-07
AR013477A1 (es) 2000-12-27

Similar Documents

Publication Publication Date Title
PE115499A1 (es) Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas de la prostaglandina f (fp)
PE123099A1 (es) Prostaglandinas tetrahidro sustituidas aromaticas c16-c20 utiles como agonistas fp
AR017077A1 (es) Compuesto de prostaglandina tetrahidro sustituido aromatico de c16-c20 util como agonista de fp y uso del mismo
BR9303878A (pt) Compostos composicao emprego processo para estabilizar um meterial organico e processo para a preparacao de compostos
PE20010953A1 (es) Derivados de pirrolidin-2-ona como agonistas selectivos del receptor ep4
DK0763049T3 (da) Nukleosid-monophosphatderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som immunundertrykkende lægemidler
AR011229A1 (es) Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.
FI961506A (fi) Distamysiini A -analogit antituumorisina ja antiviraalisina aineina
CO5040216A1 (es) Agonistas de adenosina a 1, proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20020532A1 (es) Derivados de naftaleno como agonistas del receptor canabinoide
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
ES2062486T3 (es) 3-fenilbenzofuran-2-onas.
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
ES2090400T3 (es) Agentes para preservar materiales tecnicos del ataque por insectos.
PE71599A1 (es) Inhibidores de proteasas
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
AR023381A1 (es) Nuevo derivado de tiazolbenzoimidazol
ES2028121T3 (es) Procedimiento de (co)dimerizacion de un acrilato de alquilo inferior y composicion catalitica.
ES2126581T3 (es) Derivados de 3-(piperazino-alquil)indol condensados en posiciones 1,7, asi como procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
ES2084792T3 (es) Derivados de hexahidroazepinas, un procedimiento para su preparacion y composiciones.
ES2180771T3 (es) Derivados de la quinoxalina 2,3-diona sustituidos por derivados de aminoacidos, utilizados como antagonistas de los receptores de glutamato.
ES2133153T3 (es) Nuevos depsipeptidos ciclicos con 18 atomos de anillo, y su empleo para el combate de endoparasitos.
PE20030327A1 (es) 3-5-dihidroxi-2,2-dimetil-valeronitrilos protegidos para la sintesis de epotilonas y sus derivados y metodo para su obtencion
ES2128191T3 (es) Composiciones para el teñido por oxidacion de fibras queratinicas y procedimiento de teñido que las utiliza.
PE20000725A1 (es) Compuestos de alcoxipirrolidinona como inhibidores de proteasas

Legal Events

Date Code Title Description
FX Voluntary withdrawal